285 related articles for article (PubMed ID: 25454616)
21. Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer.
van Soest RJ; de Morrée ES; Kweldam CF; de Ridder CMA; Wiemer EAC; Mathijssen RHJ; de Wit R; van Weerden WM
Eur Urol; 2015 Jun; 67(6):981-985. PubMed ID: 25484141
[TBL] [Abstract][Full Text] [Related]
22. Enzalutamide after docetaxel and abiraterone acetate treatment in prostate cancer: a pooled analysis of 10 case series.
Petrelli F; Coinu A; Borgonovo K; Cabiddu M; Ghilardi M; Lonati V; Barni S
Clin Genitourin Cancer; 2015 Jun; 13(3):193-8. PubMed ID: 25466676
[TBL] [Abstract][Full Text] [Related]
23. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.
Ryan CJ; Smith MR; Fizazi K; Saad F; Mulders PF; Sternberg CN; Miller K; Logothetis CJ; Shore ND; Small EJ; Carles J; Flaig TW; Taplin ME; Higano CS; de Souza P; de Bono JS; Griffin TW; De Porre P; Yu MK; Park YC; Li J; Kheoh T; Naini V; Molina A; Rathkopf DE;
Lancet Oncol; 2015 Feb; 16(2):152-60. PubMed ID: 25601341
[TBL] [Abstract][Full Text] [Related]
24. Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer.
Zhang T; Zhu J; George DJ; Armstrong AJ
Expert Opin Pharmacother; 2015 Mar; 16(4):473-85. PubMed ID: 25534660
[TBL] [Abstract][Full Text] [Related]
25. Improvements in Radiographic Progression-Free Survival Stratified by ERG Gene Status in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone Acetate.
Attard G; de Bono JS; Logothetis CJ; Fizazi K; Mukherjee SD; Joshua AM; Schrijvers D; van den Eertwegh AJ; Li W; Molina A; Griffin TW; Kheoh T; Ricci DS; Zelinsky K; Rathkopf DE; Scher HI; Ryan CJ
Clin Cancer Res; 2015 Apr; 21(7):1621-7. PubMed ID: 25593303
[TBL] [Abstract][Full Text] [Related]
26. Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results.
Morris MJ; Molina A; Small EJ; de Bono JS; Logothetis CJ; Fizazi K; de Souza P; Kantoff PW; Higano CS; Li J; Kheoh T; Larson SM; Matheny SL; Naini V; Burzykowski T; Griffin TW; Scher HI; Ryan CJ
J Clin Oncol; 2015 Apr; 33(12):1356-63. PubMed ID: 25624432
[TBL] [Abstract][Full Text] [Related]
27. Switching and withdrawing hormonal agents for castration-resistant prostate cancer.
Lorente D; Mateo J; Zafeiriou Z; Smith AD; Sandhu S; Ferraldeschi R; de Bono JS
Nat Rev Urol; 2015 Jan; 12(1):37-47. PubMed ID: 25563847
[TBL] [Abstract][Full Text] [Related]
28. A randomised phase 2 trial of dexamethasone versus prednisolone in castration-resistant prostate cancer.
Venkitaraman R; Lorente D; Murthy V; Thomas K; Parker L; Ahiabor R; Dearnaley D; Huddart R; De Bono J; Parker C
Eur Urol; 2015 Apr; 67(4):673-9. PubMed ID: 25457497
[TBL] [Abstract][Full Text] [Related]
29. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.
Mateo J; Carreira S; Sandhu S; Miranda S; Mossop H; Perez-Lopez R; Nava Rodrigues D; Robinson D; Omlin A; Tunariu N; Boysen G; Porta N; Flohr P; Gillman A; Figueiredo I; Paulding C; Seed G; Jain S; Ralph C; Protheroe A; Hussain S; Jones R; Elliott T; McGovern U; Bianchini D; Goodall J; Zafeiriou Z; Williamson CT; Ferraldeschi R; Riisnaes R; Ebbs B; Fowler G; Roda D; Yuan W; Wu YM; Cao X; Brough R; Pemberton H; A'Hern R; Swain A; Kunju LP; Eeles R; Attard G; Lord CJ; Ashworth A; Rubin MA; Knudsen KE; Feng FY; Chinnaiyan AM; Hall E; de Bono JS
N Engl J Med; 2015 Oct; 373(18):1697-708. PubMed ID: 26510020
[TBL] [Abstract][Full Text] [Related]
30. Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer.
Scher HI; Heller G; Molina A; Attard G; Danila DC; Jia X; Peng W; Sandhu SK; Olmos D; Riisnaes R; McCormack R; Burzykowski T; Kheoh T; Fleisher M; Buyse M; de Bono JS
J Clin Oncol; 2015 Apr; 33(12):1348-55. PubMed ID: 25800753
[TBL] [Abstract][Full Text] [Related]
31. Androgen receptor expression in circulating tumour cells from castration-resistant prostate cancer patients treated with novel endocrine agents.
Crespo M; van Dalum G; Ferraldeschi R; Zafeiriou Z; Sideris S; Lorente D; Bianchini D; Rodrigues DN; Riisnaes R; Miranda S; Figueiredo I; Flohr P; Nowakowska K; de Bono JS; Terstappen LW; Attard G
Br J Cancer; 2015 Mar; 112(7):1166-74. PubMed ID: 25719830
[TBL] [Abstract][Full Text] [Related]
32. Resistance to androgen-pathway drugs in prostate cancer.
Steinestel J; Schrader AJ; Luedeke M
N Engl J Med; 2014 Dec; 371(23):2234. PubMed ID: 25470703
[No Abstract] [Full Text] [Related]
33. Posterior reversible encephalopathy syndrome induced by enzalutamide in a patient with castration-resistant prostate cancer.
Crona DJ; Whang YE
Invest New Drugs; 2015 Jun; 33(3):751-4. PubMed ID: 25467090
[TBL] [Abstract][Full Text] [Related]
34. CYP17A1 inhibitors in castration-resistant prostate cancer.
Gomez L; Kovac JR; Lamb DJ
Steroids; 2015 Mar; 95():80-7. PubMed ID: 25560485
[TBL] [Abstract][Full Text] [Related]
35. Advances in systemic therapies for metastatic castration-resistant prostate cancer.
Pant MK; Abughaban A; Aragon-Ching JB
Future Oncol; 2014 Nov; 10(14):2213-26. PubMed ID: 25471035
[TBL] [Abstract][Full Text] [Related]
36. PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patients.
Punnoose EA; Ferraldeschi R; Szafer-Glusman E; Tucker EK; Mohan S; Flohr P; Riisnaes R; Miranda S; Figueiredo I; Rodrigues DN; Omlin A; Pezaro C; Zhu J; Amler L; Patel P; Yan Y; Bales N; Werner SL; Louw J; Pandita A; Marrinucci D; Attard G; de Bono J
Br J Cancer; 2015 Oct; 113(8):1225-33. PubMed ID: 26379078
[TBL] [Abstract][Full Text] [Related]
37. Predictive factors for response to abiraterone in metastatic castration refractory prostate cancer.
Afshar M; Al-Alloosh F; Pirrie S; Rowan C; James ND; Porfiri E
Anticancer Res; 2015 Feb; 35(2):1057-63. PubMed ID: 25667494
[TBL] [Abstract][Full Text] [Related]
38. Present, Emerging and Possible Future Biomarkers in Castration Resistant Prostate Cancer (CRPC).
Boegemann M; Schrader AJ; Krabbe LM; Herrmann E
Curr Cancer Drug Targets; 2015; 15(3):243-55. PubMed ID: 25654638
[TBL] [Abstract][Full Text] [Related]
39. Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use.
Lorente D; Mateo J; Templeton AJ; Zafeiriou Z; Bianchini D; Ferraldeschi R; Bahl A; Shen L; Su Z; Sartor O; de Bono JS
Ann Oncol; 2015 Apr; 26(4):750-755. PubMed ID: 25538172
[TBL] [Abstract][Full Text] [Related]
40. GATA2 facilitates steroid receptor coactivator recruitment to the androgen receptor complex.
He B; Lanz RB; Fiskus W; Geng C; Yi P; Hartig SM; Rajapakshe K; Shou J; Wei L; Shah SS; Foley C; Chew SA; Eedunuri VK; Bedoya DJ; Feng Q; Minami T; Mitsiades CS; Frolov A; Weigel NL; Hilsenbeck SG; Rosen DG; Palzkill T; Ittmann MM; Song Y; Coarfa C; O'Malley BW; Mitsiades N
Proc Natl Acad Sci U S A; 2014 Dec; 111(51):18261-6. PubMed ID: 25489091
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
